背景/目标:西多福韦,一种被批准用于巨细胞病毒性视网膜炎的抗病毒药物,已成为病毒诱导的皮肤和粘膜皮肤疾病的替代治疗选择,以及作为一种治疗肿瘤的试验。在这次审查中,我们强调现有的证据,临床应用,以及使用西多福韦治疗皮肤病变的基本原理。方法:进行PubMed数据库文献检索,以确定纳入本综述的相关文章。结果:西多福韦有几种皮肤应用在各种配方,包括静脉内,topic,和皮下给药。主要通过病例报告,案例系列,和回顾性审查,西多福韦已证明在治疗各种病毒引起的疾病-寻常疣的疗效,单纯疱疹病毒,传染性软疣-以及对某些肿瘤的辅助治疗。该药物已在免疫功能低下和免疫功能正常的成人和儿童中显示出疗效。结论:文献的主体支持使用西多福韦作为一种有效和耐受性良好的治疗许多病毒性皮肤病变,并鼓励进一步研究将其用作肿瘤疾病的辅助治疗。
Background/Objectives: Cidofovir, an antiviral drug approved for cytomegalovirus retinitis, has emerged as an alternative treatment option for virally induced cutaneous and mucocutaneous conditions, as well as being trialed as a treatment for select neoplasms. In this review, we highlight the existing evidence, clinical uses, and rationale of using cidofovir for the treatment of cutaneous pathologies. Methods: A PubMed database literature search was conducted to identify relevant articles for inclusion in this review. Results: Cidofovir has several cutaneous applications in various formulations including intravenous, topical, and subcutaneous administrations. Primarily through case reports, case series, and retrospective reviews, cidofovir has demonstrated efficacy in treating a variety of virally induced conditions-verruca vulgaris, herpes simplex virus, molluscum contagiosum-as well as in adjuvant treatment for select neoplasms. The drug has shown efficacy in immunocompromised and immunocompetent adults and children alike. Conclusions: The body of literature supports the use of cidofovir as an effective and well-tolerated treatment for many viral cutaneous pathologies, and encourages further study for its use as an adjuvant therapy for neoplastic disease.